Abstract
Nonionic block copolymers, synthesized from repeating units of oxypropylene and oxyethylene, can be designed so that individual copolymers have unique physical properties with differential levels of adjuvant activity. We have designed high molecular weight block copolymers that spontaneously assemble into 500 nm-3 mum particles when formulated with protein antigens in aqueous solutions at physiological pH. The adjuvant activity of one of these copolymers, termed CRL1005, was compared to selected research adjuvants using ovalbumin (OVA) as the prototype vaccine antigen. Suboptimal doses of OVA were formulated with complete and incomplete. Freund's adjuvant (CFA/IFA), alum Quil-A saponins Ribi Adjuvant System (RAS) or the CRL1005 copolymer and these formulations were used to immunize C57BL/6 mice. The CRL1005 copolymer appeared to be more potent than either Quil-A or alum and comparable to the RAS formulation, based on the numbers of responding mice and the OVA-specific antibody titers. Alum. RAS and Quil-A all augmented the production of IgG1 and IgG2l, similarly whereas only the CFA/IFA boosted IgG2a levels significantly. The effect of adjuvants on relative antibody affinity was more variable with the CRL1005 and CFA/IFA induci...Continue Reading
References
Jan 1, 1978·Cellular Immunology·C DamaisJ Choay
Feb 1, 1976·Cellular Immunology·F AudibertJ Choay
Jan 1, 1992·Vaccine·A W Heath, J H Playfair
Mar 1, 1991·Molecular Immunology·J H EldridgeR M Gilley
Feb 10, 1988·Journal of Immunological Methods·R A MacdonaldC L Jones
Apr 15, 1986·Cellular Immunology·L M Flebbe, H Braley-Mullen
Apr 15, 1986·Cellular Immunology·L M Flebbe, H Braley-Mullen
Jun 1, 1987·Vaccine·G GregoriadisA Davies
Dec 4, 1986·Journal of Immunological Methods·J KohnJ G Fox
Mar 1, 1986·Scandinavian Journal of Immunology·R L Hunter, B Bennett
Jun 1, 1985·Vaccine·L F Woodard, R L Jasman
Nov 15, 1974·Nature·A G Allison, G Gregoriadis
Aug 1, 1995·AIDS Research and Human Retroviruses·L B LachmanJ L Cleland
Nov 1, 1994·Vaccine·P O LivingstonD Marciani
Jan 1, 1994·Biotherapy·A Nohria, R H Rubin
Jan 14, 1994·Science·L C AfonsoP Scott
Jan 1, 1994·The Journal of General Virology·V E SchijnsA D Osterhaus
Oct 1, 1993·Immunology and Cell Biology·A D NashA E Andrews
Apr 1, 1993·Immunobiology·C R Alving
Jan 1, 1993·Cancer Immunology, Immunotherapy : CII·G D MacLeanB M Longenecker
Jan 1, 1993·Vaccine·A Tagliabue, D Boraschi
Citations
Apr 12, 2002·Biotechnology and Bioengineering·Ales ProkopMark J Newman
May 20, 2004·Vaccine·Ya-Wun YangW J W Morrow
Aug 23, 2001·Journal of Controlled Release : Official Journal of the Controlled Release Society·V P Torchilin
Jun 6, 2000·Advanced Drug Delivery Reviews·C W ToddM J Newman
Oct 12, 2000·Vaccine·S K KimP O Livingston
Oct 16, 1999·Vaccine·J G LanierR Ahmed
Nov 5, 1999·Vaccine·S K KimP O Livingston
Nov 21, 1998·AIDS Research and Human Retroviruses·J M McNichollR L Hunter
Nov 23, 2012·Journal of the Royal Society, Interface·Akhilesh Kumar Shakya, Kutty Selva Nandakumar
Nov 14, 2001·Infection and Immunity·J Y WuR K Taylor
Oct 11, 2007·Malaria Journal·George JiangDenise L Doolan
Jun 19, 2001·Biological Chemistry·W ZaunerM Buschle
Nov 13, 1998·Journal of Pharmaceutical Sciences·M J NewmanM Balusubramanian
Mar 13, 2009·Journal of Biomedical Materials Research. Part B, Applied Biomaterials·Ming-Hsi HuangChih-Hsiang Leng
Mar 7, 2009·The Journal of General Virology·William J MullerDavid M Koelle
Apr 22, 2008·The Journal of Gene Medicine·Jukka HartikkaAlain Rolland
Jan 16, 2010·Journal of Controlled Release : Official Journal of the Controlled Release Society·Elena V BatrakovaAlexander V Kabanov
Nov 27, 2009·Nature·Jeffrey A HubbellMelody A Swartz
Jun 2, 2020·Expert Opinion on Drug Delivery·Rosana Simón-VázquezÁfrica González-Fernández